Hemwattie Jaimangal, DO
Infectious Disease · Lady Lake, FLNPI 1821019001
Payments from drug & device makers
What this record shows
Insmed, Inc. accounts for 62.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $155 and has fallen 59.8% since, to $62 in 2025. That places this record below the midpoint for infectious disease clinicians in FL, where the typical reported total is $652.
Across 16 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$261
- Paratek Pharmaceuticals, Inc.$82
- Cumberland Pharmaceuticals, Inc.$38
- Merck$26
- Melinta Therapeutics, LLC$13
What the payments were for
- Food & beverage$19045%
- Education$23055%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 8 | $261 |
| Paratek Pharmaceuticals, Inc. | 4 | $82 |
| Cumberland Pharmaceuticals, Inc. | 1 | $38 |
| Merck | 2 | $26 |
| Melinta Therapeutics, LLC | 1 | $13 |
How this compares
$420 in reported general payments places this provider in the 40th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 19 | $287,601 |
| DificidFidaxomicin | 24 | $283,980 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $52,078 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 11 | $46,332 |
| Fosfomycin Tromethamine | 85 | $12,949 |
| Vancomycin Hcl | 53 | $11,191 |
| Daptomycin | 47 | $9,682 |
| Clarithromycin | 58 | $6,264 |
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 11 | $5,620 |
| Cefepime Hcl | 34 | $3,008 |
| CefuroximeCefuroxime Axetil | 100 | $2,689 |
| Methenamine Hippurate | 17 | $1,770 |
| Doxycycline Hyclate | 55 | $1,649 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 16 | $1,418 |
| Meropenem | 21 | $1,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $261 | $287,60119 claims |
| MerckDificid | $26 | $283,98024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Lady Lake
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Christopher CooperAltamonte Springs$278K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
- Sally AlrabaaTampa$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.